Susvimo (ranibizumab)

Brand name: Susvimo

Generic: ranibizumab

Susvimo (ranibizumab) injection is a prescription ophthalmic medicine used to treat the symptoms of neovascular (wet) age-related macular degeneration (AMD), which may cause vision loss (blindness). Susvimo is delivered via ocular implant.

Susvimo is a vascular endothelial growth factor A (VEGF-A) antagonist, which may be used alone or with other medications.

It is not known if Susvimo is safe and effective in children.

Susvimo may cause serious side effects including:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• severe eye pain,
• redness in the white of the eye,
• extreme sensitivity to bright light,
• decreased vision,
• swelling of the eyelid,
• floaters in the eye,
• sudden flashes of light,
• shadows in the vision field,
• implant dislocation,
• cloudy vision,
• lines or dark dots in your vision,
• dry or irritated eyes,
• feeling like something is in your eye,
• difficulty closing your eye,
• postoperative decrease in visual acuity,
• air bubbles causing improper filling of the implant, and
• deflection of the implant

Get medical help right away, if you have any of the symptoms listed above.

The most common side effects of Susvimo include:

• redness of the eye,
• itching,
• feeling like something is in your eye,
• tearing of the eye,
• eye pain,
• reduced vision,
• headache,
• abnormally shaped pupils,
• sensitivity to light,
• vision loss, and
• eye pain

Tell the doctor if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of Susvimo. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

No information provided

• For Intravitreal Use via Susvimo ocular implant.
• The Susvimo initial fill and ocular implant insertion and implant removal procedures must be performed under aseptic conditions by a physician experienced in vitreoretinal surgery. The Susvimo ocular implant must be surgically implanted in the eye or removed from the eye (if medically necessary) in an operating room using aseptic technique. See Susvimo Instructions for Use and the standardized steps to optimize surgical outcomes.
• Susvimo refill-exchange procedures must be performed under aseptic conditions by a physician experienced in ophthalmic surgery.
• Do not administer Susvimo (ranibizumab injection) as a bolus intravitreal injection. Do not substitute Susvimo (ranibizumab injection) with other ranibizumab products.

Before receiving Susvimo, tell your healthcare provider about all of your medical conditions, including if you:

• are currently taking or have recently taken medicines that lower the chance of blood clots forming in the body such as warfarin, low or regular doses of aspirin, or nonsteroidal anti-inflammatory drugs (NSAID).
• are pregnant or plan to become pregnant. It is not known if Susvimo will harm your unborn baby. You should use birth control during your treatment with Susvimo and for 12 months after your last dose of Susvimo.
• are breastfeeding or plan to breastfeed. It is not known if Susvimo passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive Susvimo.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.